RNTX’s LTI-03 advances global Phase II for IPF
LTI-03, an inhaled peptide for idiopathic pulmonary fibrosis (IPF), is enrolling globally in Phase II; interim data are expected this year and full results late 2027.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.